Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

Aims: To compare functional and anatomical outcomes of intravitreal bevacizumab (Avastin) and verteporfin (photodynamic) therapy (PDT) combined with intravitreal triamcinolone (IVTA) in patients with neovascular age-related macular degeneration (AMD).Methods: Twenty-eight patients with neovascular A...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of ophthalmology 2008-03, Vol.92 (3), p.356-360
Hauptverfasser:	Weigert, G, Michels, S, Sacu, S, Varga, A, Prager, F, Geitzenauer, W, Schmidt-Erfurth, U
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Biological and medical sciences Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Choroidal Neovascularization - pathology Choroidal Neovascularization - physiopathology Clinical trials Diabetic retinopathy Diseases of the skin. Cosmetics Female Glucocorticoids - therapeutic use Humans Macular degeneration Macular Degeneration - complications Macular Degeneration - drug therapy Macular Degeneration - pathology Macular Degeneration - physiopathology Male Medical imaging Medical sciences Middle Aged Miscellaneous Ophthalmology Pharmaceutical industry Photochemotherapy - methods Prospective Studies Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Retina - pathology Retinopathies Studies Tomography, Optical Coherence Treatment Outcome Triamcinolone - therapeutic use Variance analysis Vascular endothelial growth factor Visual Acuity - drug effects Vitreous Body
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!